Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.
Therapeutic Advances in Medical Oncology|March 29, 2020
An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)Xiang Wang, Ruixing Zhang, Nan Du, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2025
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Lin Shen, Jie Li, et al.
American Journal of Cancer Research|April 9, 2020
Safety and effectiveness of apatinib in patients with previously treated metastatic gastric cancer: a sub-analysis from the real-world study of apatinib for gastric cancer treatment (AHEAD-G202)Xiang Wang, Junyan Yu, Mudan Yang, et al.
Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.
Cancer Communications (London, England)|October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II studyZhi Peng, Tianshu Liu, Jia Wei, et al.
Nature Communications|February 15, 2022
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)Jianming Xu, Yi Li, Qingxia Fan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2025
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trialChunmei Bai, Yi Zheng, Meili Sun, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
The Lancet. Respiratory Medicine|December 1, 2025
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trialJia Zhong, Jun Zhao, Jianchun Duan, et al.
Pageof 17